ReviewNPJ breast cancer2023

Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer.

Giuseppe Curigliano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.